Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.49 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.49 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.49 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27729083 | 0.91 | CYP1A2 (0.49) | CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2 | |
| SCHEMBL3106784 | 0.90 | CYP1A2 (0.51) | CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2 | |
| SCHEMBL3106563 | 0.88 | HDAC1 (0.47) | CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2 | |
| SCHEMBL3106936 | 0.85 | ALDH1A1 (0.48) | CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2 | |
| SCHEMBL3109783 | 0.83 | KCNQ2 (0.44) | CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2 | |
| SCHEMBL6005016 | 0.82 | CYP1A2 (0.51) | CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL11451154 | 0.78 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2 | |
| SCHEMBL6005056 | 0.76 | HDAC3 (0.53) | CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2 | |
| SCHEMBL11302948 | 0.75 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2 | |
| SCHEMBL20129836 | 0.75 | KCNQ2 (0.83) | CYP1A2CYP2C9CYP2C19SMN1; SMN2KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| CN-101790374-A | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted | LUNDBECK & CO AS H | 2010-07-28 | — | — | CN | claimed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | claimed |
| US-20060167087-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | claimed |
| EP-1606247-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. Lundbeck A/S (DK) | 2005-12-21 | — | — | EP | claimed |
| WO-2004080950-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-09-23 | — | — | WO | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| CN-101378742-B | Use of KCNQ-openers for the preparation of a pharmaceutical composition for the treatment of schizophrenia | LUNDBECK & CO AS H | 2013-07-10 | — | — | CN | disclosed |
| EP-2554162-A1 | Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia | H. Lundbeck A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | disclosed |
| CN-101378742-A | Use of KCNQ-openers for treating or alleviating the symptoms of schizophrenia | LUNDBECK & CO AS H (DK) | 2009-03-04 | — | — | CN | disclosed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | disclosed |
| EP-1983974-A1 | USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. Lundbeck A/S (DK) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007090409-A1 | USE OF KCNQ-OPENERS FOR THREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
| US-20060167087-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| EP-1606247-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. Lundbeck A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080950-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167087-A1 | Substituted aniline derivatives | CYP3A43, UGT2B7, CYP3A7 | CYP1A2 9/4885CYP2C9 12/4885CYP2C19 11/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | CYP1A2 1315/4885CYP2C9 3138/4885CYP2C19 2169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.